Population Health Approach to Optimizing Medications in Older Adults (NCT06110156) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Population Health Approach to Optimizing Medications in Older Adults
United States100 participantsStarted 2025-05-19
Plain-language summary
This randomized controlled pragmatic pilot study examines the feasibility and acceptability of a population health-based deprescribing intervention that leverages a polypharmacy risk prediction model. It includes four arms (2 intervention and 2 control arms) and uses a parallel arm study design.
Who can participate
Age range65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients will be invited to enroll in the study if they are in the top decile of risk selected by a risk prediction model of polypharmacy-related adverse events. The risk prediction model includes variables such as: age, sex, recent healthcare encounters, current and past medications, current and past lab tests, current and past diagnoses.
* 65 years of age or older
* Have a primary care clinician within the Cedars-Sinai Health System who uses MyCSLink (electronic health record used by Cedars-Sinai).
* Part of a Cedars-Sinai Health System population health registry (e.g., enrolled in an Accountable Care Organization, Medicare Advantage plan, or Primary Care First program)
* Diagnosis of Mild Cognitive Impairment or Dementia at baseline (for one intervention group) on the problem list
Exclusion criteria include:
* Patients for whom there is an active substance use disorder (defined by a physician) and thus for whom the intervention may not be appropriate
* Patients with an organ transplant
* Visits with a Cedars-Sinai Medical Center pharmacist for a polypharmacy consult within the last 6 months
* Patients who previously indicated in the EHR that they wish to opt out of participating in research studies.
* Patients enrolled in CS360, a program for highly complex medical patients, who already receive polypharmacy services.